BMO Capital Starts DexCom (DXCM) at Outperform

September 16, 2016 8:47 AM EDT
Get Alerts DXCM Hot Sheet
Price: $93.91 -0.12%

Rating Summary:
    14 Buy, 10 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 15 | Down: 13 | New: 71
Trade DXCM Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

BMO Capital initiates coverage on DexCom (NASDAQ: DXCM) with a Outperform rating and a price target of $112.00.

Analyst Joanne Wuensch commented, "DexCom has revolutionized the treatment of diabetes with its continuous glucose monitoring (CGM) systems that solve many of the limitations of traditional finger stick testing by providing a “continuous” series of glucose readings, displaying a trend line graph and allowing real-time alerts and alarms."

She added, "DXCM shares are not cheap, nor should they be, trading at 9.6x 2017E EV/ revenue versus the peer group’s 7.0x average. With an estimated growth rate of 38% versus the peer group average of 25%, the company has consistently delivered revenue, and we believe that it has a long runway ahead of it. Admittedly, the multiple sounds high, but it is actually hovering at its five-year average of 9.9x (the range is wide - 3.7-16.7x). Our price target is based on: 1) 11.5x 2017E EV/revenue ($111/share); 2) 9.5x 2018E EV/revenue, discounted back one year ($115); and 3) a DCF analysis ($112)."

For an analyst ratings summary and ratings history on DexCom click here. For more ratings news on DexCom click here.

Shares of DexCom closed at $92.75 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, New Coverage

Related Entities

BMO Capital

Add Your Comment